

Sascha Gerdes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5586673/publications.pdf>

Version: 2024-02-01

98
papers

3,300
citations

201385

27
h-index

168136

53
g-index

123
all docs

123
docs citations

123
times ranked

4529
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. <i>Journal of Advanced Research</i> , 2023, 44, 71-79.	4.4	9
2	Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. <i>Dermatologic Therapy</i> , 2022, 35, e15193.	0.8	2
3	Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients. <i>Dermatology</i> , 2022, 238, 615-619.	0.9	26
4	Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 385-395.	1.5	17
5	Another anti-interleukin (IL) 17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?. <i>British Journal of Dermatology</i> , 2022, 186, 603-604.	1.4	0
6	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: a post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1774-1783.	1.3	7
7	Psoriasis-Therapie während Schwangerschaft und Stillzeit. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 653-685.	0.4	0
8	Therapy of psoriasis during pregnancy and breastfeeding. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 653-683.	0.4	6
9	Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1-year of treatment with guselkumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1568-1577.	1.3	8
10	Measuring wellbeing in psoriasis: psychometric properties of the WHO-5 questionnaire. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	2
11	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2181-2189.	1.3	4
12	Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 878-882.	1.1	24
13	Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 431-440.	1.3	20
14	Atopic dermatitis displays stable and dynamic skin transcriptome signatures. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 213-223.	1.5	76
15	Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study. <i>Dermatologic Therapy</i> , 2021, 34, e14814.	0.8	32
16	Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 28-34.	1.3	5
17	Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1306-1311.	0.5	289
18	Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1959-1965.e2.	1.5	17

#	ARTICLE	IF	CITATIONS
19	A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2045-2050.	1.3	13
20	Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement*. <i>British Journal of Dermatology</i> , 2021, 185, 605-615.	1.4	8
21	ActiPso: definition of activity types for psoriatic disease: A novel marker for an advanced disease classification. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2027-2033.	1.3	3
22	Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial. <i>Nutrients</i> , 2021, 13, 3015.	1.7	7
23	Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2079-2083.	0.3	3
24	Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. <i>Journal of Dermatology</i> , 2021, 48, 1854-1862.	0.6	24
25	Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1451-1461.	0.4	9
26	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). <i>Journal of Dermatological Treatment</i> , 2021, 32, 883-893.	1.1	11
27	Long-term efficacy: the new gold standard?. <i>British Journal of Dermatology</i> , 2021, 185, 1086.	1.4	0
28	Rare variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4. <i>Nature Communications</i> , 2021, 12, 6618.	5.8	17
29	Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2). <i>Journal of Drugs in Dermatology</i> , 2021, 20, 880-887.	0.4	3
30	Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. <i>RMD Open</i> , 2021, 7, e002008.	1.8	28
31	Adiponectin levels in a large pooled plaque psoriasis study population. <i>Journal of Dermatological Treatment</i> , 2020, 31, 531-534.	1.1	17
32	Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 769-775.	1.1	31
33	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). <i>British Journal of Dermatology</i> , 2020, 183, 265-275.	1.4	24
34	Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1208-1218.	1.5	29
35	Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 533-541.	1.3	47
36	Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1406-1415.	1.5	103

#	ARTICLE	IF	CITATIONS
37	Two questions may be enough – screening for depression in patients with psoriasis: a multicenter study. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1115-1125.	0.4	7
38	Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. Dermatology and Therapy, 2020, 10, 589-613.	1.4	49
39	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy, 2020, 10, 431-447.	1.4	40
40	Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. Journal of Dermatological Treatment, 2020, 31, 470-475.	1.1	30
41	Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients. Journal of Dermatology, 2020, 47, 989-997.	0.6	17
42	The efficacy of secukinumab with continued use in the treatment of psoriasis. British Journal of Dermatology, 2020, 182, e22-e22.	1.4	0
43	Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2548-2556.	1.3	10
44	Profiles of psychosocial variables and dental status in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e586-e587.	1.3	2
45	Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatology Online Journal, 2020, 26, .	0.2	1
46	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015. PLoS ONE, 2019, 14, e0220108.	1.1	31
47	S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 856-870.	0.4	18
48	S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2. JDDG - Journal of the German Society of Dermatology, 2019, 17, 959-973.	0.4	24
49	Drug Survival und Gründe für einen Therapieabbruch bei Pustulosis palmoplantaris: Eine retrospektive multizentrische Studie. JDDG - Journal of the German Society of Dermatology, 2019, 17, 503-517.	0.4	3
50	368 The microbiota of atopic dermatitis lesions induces TSLP expression in a 3D skin equivalent. Journal of Investigative Dermatology, 2019, 139, S278.	0.3	0
51	Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. JDDG - Journal of the German Society of Dermatology, 2019, 17, 503-516.	0.4	20
52	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. European Journal of Cancer, 2019, 111, 148-154.	1.3	197
53	Oral Health in Patients with Psoriasis – A Prospective Study. Journal of Investigative Dermatology, 2019, 139, 1237-1244.	0.3	22
54	Continued treatment with secukinumab is associated with high retention or regain of response. British Journal of Dermatology, 2019, 182, 67-75.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , 2019, 113, 47-54.	1.3	300
56	Topische Therapie bei Psoriasis vulgaris – ein Behandlungspfad. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 3-14.	0.4	31
57	Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, AB38.	0.6	1
58	Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 906-912.	0.4	8
59	Biosimilars in der Dermatologie – Theorie wird Realität. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 150-162.	0.4	2
60	Biosimilars in Dermatology – theory becomes reality. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 150-160.	0.4	7
61	When to switch biologics: some answers, but lots of questions too. <i>British Journal of Dermatology</i> , 2018, 178, 20-20.	1.4	0
62	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 420-427.	1.3	70
63	The genetic basis for most patients with pustular skin disease remains elusive. <i>British Journal of Dermatology</i> , 2018, 178, 740-748.	1.4	82
64	Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare). <i>Acta Dermato-Venereologica</i> , 2018, 98, 200-205.	0.6	23
65	Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1100-1105.	1.1	27
66	Put the ducks in a row - which biologic to use first?. <i>British Journal of Dermatology</i> , 2018, 179, 241-242.	1.4	0
67	002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, S193.	0.3	4
68	Switching expensive drugs with frequently diminishing value. <i>British Journal of Dermatology</i> , 2017, 177, 338-339.	1.4	1
69	Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 679-685.	1.3	46
70	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
71	Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions. <i>Dermatology</i> , 2017, 233, 425-434.	0.9	31
72	Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman. <i>Acta Dermato-Venereologica</i> , 2017, 97, 283-284.	0.6	24

#	ARTICLE	IF	CITATIONS
73	Palmoplantar pustulosis – a cross-sectional analysis in Germany. <i>Dermatology Online Journal</i> , 2017, 23, .	0.2	26
74	A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price. <i>British Journal of Dermatology</i> , 2016, 174, 1183-1184.	1.4	0
75	Online weight-loss coaching for patients with psoriasis: results of a pilot study. <i>British Journal of Dermatology</i> , 2016, 174, 674-676.	1.4	4
76	052 Efficacy of ixekizumab in moderate-to-severe psoriasis patients who have or have not received prior biologic therapies: An integrated analysis of 3 phase 3 studies. <i>Journal of Investigative Dermatology</i> , 2016, 136, S169.	0.3	4
77	Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. <i>Archives of Dermatological Research</i> , 2016, 308, 249-261.	1.1	9
78	Systemic Antipsoriatic Combination Therapy with Fumaric Acid Esters for Plaque-Type Psoriasis: Report on 17 Cases. <i>Dermatology</i> , 2015, 230, 119-127.	0.9	9
79	Wnt5a - a potential factor linking psoriasis to metabolic complications. <i>Experimental Dermatology</i> , 2014, 23, 439-440.	1.4	18
80	Psoriasis: to treat or to manage?. <i>Experimental Dermatology</i> , 2014, 23, 705-709.	1.4	70
81	Cardiovascular biomarkers in patients with psoriasis. <i>Experimental Dermatology</i> , 2014, 23, 322-325.	1.4	39
82	Systemic Treatment with Fumaric Acid Esters in Six Paediatric Patients with Psoriasis in a Psoriasis Centre. <i>Dermatology</i> , 2014, 229, 199-204.	0.9	18
83	Bacterial soft tissue infection in psoriasis despite induction of epidermal antimicrobial peptides. <i>Experimental Dermatology</i> , 2014, 23, 862-864.	1.4	6
84	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
85	Zonulin May Not be a Marker of Autoimmunity in Patients with Psoriasis. <i>Acta Dermato-Venereologica</i> , 2012, 92, 171-172.	0.6	4
86	Combination of adalimumab with traditional systemic antipsoriatic drugs – a report of 39 cases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 821-837.	0.4	20
87	Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 424-436.	1.1	132
88	Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. <i>European Journal of Cancer</i> , 2012, 48, 695-702.	1.3	55
89	Leptin, adiponectin, visfatin and retinol-binding protein – mediators of comorbidities in patients with psoriasis?. <i>Experimental Dermatology</i> , 2012, 21, 43-47.	1.4	78
90	Adipokines and psoriasis. <i>Experimental Dermatology</i> , 2011, 20, 81-87.	1.4	126

#	ARTICLE	IF	CITATIONS
91	Long-Term Treatment with Fumaric Acid Esters in an 11-Year-Old Male Child with Psoriasis. <i>Dermatology</i> , 2011, 222, 198-200.	0.9	17
92	Ustekinumab in the treatment of palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 2010, 163, 1116-1118.	1.4	67
93	Smoking and Alcohol Intake in Severely Affected Patients with Psoriasis in Germany. <i>Dermatology</i> , 2010, 220, 38-43.	0.9	92
94	Impact of Comorbidities on the Management of Psoriasis. <i>Current Problems in Dermatology</i> , 2009, 38, 21-36.	0.8	19
95	Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis. <i>British Journal of Dermatology</i> , 2009, 160, 736-740.	1.4	14
96	Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 1116-23.	1.4	60
97	Dimethylfumarate inhibits nuclear binding of nuclear factor κ B but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein γ in activated human T cells. <i>British Journal of Dermatology</i> , 2007, 156, 838-842.	1.4	69
98	Follicular rash during therapy with erlotinib (Tarceva [®] 1/2). <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 855-857.	0.4	1